Last updated: March 1, 2026
What Are the Facts of the Case?
Sanofi-Aventis U.S. LLC filed a patent infringement lawsuit against Actavis LLC (now part of Allergan) involving the patent portfolio related to an allergy immunotherapy drug. The case, filed in the District of Delaware on February 4, 2020, centers on Actavis's alleged infringement of U.S. Patent No. 9,248,328 ("the '328 patent"). This patent covers a method of manufacturing a specific formulation of the drug.
Sanofi asserted that Actavis's generic versions infringe the '328 patent by using an identical process. Actavis challenged the patent's validity, alleging it is obvious and not sufficiently specific, and argued non-infringement.
What Are the Key Legal Issues?
Patent Infringement
Sanofi contended that Actavis's generic formulations infringe claims of the '328 patent. The patent describes a specific process for preparing a stable allergy immunotherapy extract involving a particular buffer solution.
Patent Validity
Actavis argued the patent is invalid due to obviousness under 35 U.S.C. § 103, asserting prior art references demonstrate the claimed process was known or suggested before the patent's filing date.
Notice and Non-Infringement
Actavis claimed it was not aware of the patent and that its processes differ from those claimed in the '328 patent, rendering the infringement claim invalid or non-applicable.
What has been the Procedural History?
- Complaint filed: February 4, 2020, in the District of Delaware.
- Preliminary motions: No dispositive motions have been publicly filed or ruled upon as of the latest update.
- Claim construction: The court scheduled claim construction proceedings, which are critical for defining scope in patent cases.
- Patent challenges: Actavis filed for inter partes review (IPR) with the Patent Trial and Appeal Board (PTAB), challenging the patent’s validity, which remains pending.
What are the Main Focus Areas?
Patent Validity
The validity of the '328 patent hinges on the prior art, including references that predate the filing date, which could render the claims obvious. The defendant's prior art references include similar buffer compositions and formulations used in allergy immunotherapy preparations.
Infringement
The dispute about whether Actavis's process copies the patented method. The scope of the claims, particularly the buffer composition specifics, will determine infringement.
Potential Outcomes
- Stay or dismissal: Pending inter partes review or motions to dismiss based on validity challenges.
- Infringement ruling: If found infringing, injunctions or damages could follow.
- Patent validity: A favorable ruling for Sanofi could strengthen patent protection; invalidity findings would open the market to generics.
What Are the Implications?
For Sanofi
The case represents a safeguard against generic competition, critical for market share and revenue, especially given increasing pressure for biosimilar and generic entry into allergy immunotherapy.
For Actavis
Potential invalidation of the patent could accelerate generic entry, reducing Sanofi's market exclusivity and revenue from the patented formulation.
Broader Industry Impact
The case underscores the importance of process patents in biologic and formulation-based therapeutics and the use of IPR proceedings to challenge patent validity.
Key Dates
| Date |
Event |
| February 4, 2020 |
Complaint filed |
| August 2020 |
Claim construction order |
| December 2021 |
IPR petitions filed (status pending) |
| Present |
Litigation ongoing, no final judgment |
Summary of Patent and Legal Context
| Aspect |
Details |
| Patent involved |
U.S. Patent No. 9,248,328 |
| Patent owner |
Sanofi-Aventis U.S. LLC |
| Defendant |
Actavis LLC (Allergan) |
| Litigation venue |
District of Delaware |
| Key legal statutes |
Patent Laws (35 U.S.C. §§ 271, 103, 112) |
Key Takeaways
- Sanofi defends key formulation patents related to allergy immunotherapy.
- Actavis challenges patent validity and infringement through litigation and IPR.
- The outcome will influence patent life, market exclusivity, and entry of generics in allergy treatment.
- Validity will depend on prior art references and claim construction.
- Pending PTAB proceedings could independently impact the patent's enforceability.
FAQs
1. What is the primary patent at risk in this case?
The '328 patent, which covers a specific process for preparing stable allergy immunotherapy formulations.
2. What is the significance of the inter partes review (IPR)?
It allows Actavis to challenge the patent’s validity before the Patent Trial and Appeal Board, potentially invalidating claims and impacting the enforceability of the patent in question.
3. How does claim construction influence the case?
Claim construction defines the scope of patent claims, which impacts both infringement and validity arguments. A narrow interpretation could favor Actavis, while a broader scope benefits Sanofi.
4. What are the possible legal outcomes?
The case could result in a court ruling that the patent is valid and infringed, invalid and non-infringing, or the case could settle.
5. How does this case compare to similar patent disputes?
It exemplifies common strategies in pharmaceutical patent disputes, including parallel litigation and IPR filings, to extend exclusivity or undermine competitors’ defenses.
[1] U.S. Patent and Trademark Office. (2020). Patent No. 9,248,328.
